Find Clinical Trial
Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study.
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Cardiovascular Diseases |
| Indication | Coronary Artery Disease |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
IVABRADINE, |
| Active Substance Code | S016257 |
| Protocol Code | CL3-16257-067 |
| EudraCT Code | 2006-005475-17 |
| ISRCTN Code | ISRCTN99185656 |
Documents and links
| Results summary | READ MORE  |
| Scientific publication | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
